Filing Details

Accession Number:
0001479290-18-000054
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-03-16 20:35:42
Reporting Period:
2018-03-16
Accepted Time:
2018-03-16 20:35:42
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1479290 Revance Therapeutics Inc. RVNC () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1238646 Phyllis Gardner C/O Revance Therapeutics, Inc
7555 Gateway Boulevard
Newark CA 94560
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-03-16 4,000 $2.55 7,000 No 4 M Direct
Common Stock Acquisiton 2018-03-16 1,333 $2.55 8,333 No 4 M Direct
Common Stock Disposition 2018-03-16 5,333 $31.51 3,000 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Common Stock Acquisiton 2018-03-16 4,000 $0.00 4,000 $2.55
Common Stock Common Stock Acquisiton 2018-03-16 1,333 $0.00 1,333 $2.55
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2018-04-29 No 4 M Direct
0 2020-07-20 No 4 M Direct
Footnotes
  1. The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.50 to $31.55. Dr. Gardner undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  2. The option is fully vested as of January 1, 2012.
  3. The Option is fully vested as of January 1, 2014.